A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer.

BACKGROUND Eribulin mesylate is a non-taxane microtubule dynamics inhibitor that recently gained Food and Drug Administration approval for late-line metastatic breast cancer (MBC). PATIENTS AND METHODS In this single-arm, multicentre open-label phase II trial Japanese patients pretreated with an anthracycline and a taxane received 1.4 mg/m(2) eribulin mesylate (2- to 5-min i.v. infusion on days 1 and 8 of a 21-day cycle). The primary efficacy end point was overall response rate (ORR) by independent review. RESULTS Patients (N = 80) had received a median of three prior chemotherapy regimens (range 1-5). ORR was 21.3% [95% confidence interval (CI) 12.9-31.8; all partial responses (PRs)], stable disease (SD) occurred in 30 patients (37.5%) and the clinical benefit rate (complete response + PR + SD ≥6 months) was 27.5% (95% CI 18.1-38.6). Median duration of response was 3.9 months (95% CI 2.8-4.9), progression-free survival was 3.7 months (95% CI 2.0-4.4) and overall survival was 11.1 months (95% CI 7.9-15.8). The most frequent treatment-related grade 3/4 adverse events were neutropenia (95.1%), leukopenia (74.1%) and febrile neutropenia (13.6%). Grade 3 peripheral neuropathy occurred in 3.7% of patients (no grade 4). CONCLUSIONS Eribulin exhibited efficacy and tolerability in Japanese patients with heavily pretreated MBC.

[1]  J. Harvey,et al.  Breast cancer—facts and figures , 2013 .

[2]  T. Mukohara,et al.  Eribulin mesylate in patients with refractory cancers: a Phase I study , 2011, Investigational New Drugs.

[3]  Y. Wong,et al.  Interactions between the chemotherapeutic agent eribulin mesylate (E7389) and P-glycoprotein in CF-1 abcb1a-deficient mice and Caco-2 cells , 2011, Xenobiotica; the fate of foreign compounds in biological systems.

[4]  J. Thigpen.  Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study , 2011 .

[5]  D. Toppmeyer,et al.  Ixabepilone, a New Treatment Option for Metastatic Breast Cancer , 2010, American journal of clinical oncology.

[6]  R. Paridaens,et al.  Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Wanders,et al.  Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. , 2010, Clinical breast cancer.

[8]  Leslie Wilson,et al.  Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. , 2010, Biochemistry.

[9]  A. Kohút,et al.  MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome , 2010, The Pharmacogenomics Journal.

[10]  H. Iwata,et al.  Phase II study of gemcitabine monotherapy as a salvage treatment for Japanese metastatic breast cancer patients after anthracycline and taxane treatment. , 2009, Japanese journal of clinical oncology.

[11]  T. Wakamatsu,et al.  Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies , 2009, British Journal of Cancer.

[12]  M Eileen Dolan,et al.  Cancer Pharmacoethnicity: Ethnic Differences in Susceptibility to the Effects of Chemotherapy , 2009, Clinical Cancer Research.

[13]  David A. Smith,et al.  Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  C. Takimoto,et al.  A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies , 2009, Clinical Cancer Research.

[15]  Y. Wong,et al.  Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors Cancer Therapy: Clinical , 2022 .

[16]  E. Perez,et al.  Treatment options for breast cancer resistant to anthracycline and taxane. , 2009, Mayo Clinic proceedings.

[17]  C. Ishioka,et al.  Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes , 2008, Cancer Chemotherapy and Pharmacology.

[18]  M. Jordan,et al.  Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase , 2008, Molecular Cancer Therapeutics.

[19]  J. Arezzo,et al.  Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. , 2008, Clinical advances in hematology & oncology : H&O.

[20]  Melvin J. Yu,et al.  Antiproliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxel-resistant human cancer cells in vitro , 2007 .

[21]  M. Piccart,et al.  Achievements in systemic therapies in the pregenomic era in metastatic breast cancer. , 2007, The oncologist.

[22]  G. Hortobagyi,et al.  Overview of resistance to systemic therapy in patients with breast cancer. , 2007, Advances in experimental medicine and biology.

[23]  M. Jordan,et al.  The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth , 2005, Molecular Cancer Therapeutics.

[24]  J. Doroshow,et al.  A phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: A California Cancer Consortium trial , 2005 .

[25]  T. Tabei,et al.  Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes. , 2005, Japanese journal of clinical oncology.

[26]  Melvin J. Yu,et al.  Induction of Morphological and Biochemical Apoptosis following Prolonged Mitotic Blockage by Halichondrin B Macrocyclic Ketone Analog E7389 , 2004, Cancer Research.

[27]  Melvin J. Yu,et al.  In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. , 2001, Cancer research.

[28]  J. Doroshow,et al.  A California Cancer Consortium phase II trial of concurrent twice-weekly paclitaxel, weekly carboplatin and radiation followed by paclitaxel/carboplatin consolidation for stage III non-small-cell lung cancer , 2000 .

[29]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[30]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.